XML 68 R52.htm IDEA: XBRL DOCUMENT
v3.22.4

Acquisitions (Asset Acquisitions) (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Feb. 28, 2022 | Dec. 31, 2021 | Mar. 31, 2021 | Jan. 31, 2021 | Oct. 31, 2020 | May 31, 2020 | Dec. 31, 2022
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  |  | $ 333.8
BioMarin Pharmaceutical Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense | $ 110.0 |  |  |  |  |  |
Foghorn Therapeutics Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  | $ 316.6 |  |  |  |  |
Rigel Pharmaceuticals, Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  | $ 125.0 |  |  |  |
Precision Biosciences, Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  | $ 107.8 |  |  |
Innovent Biologics, Inc. (Innovent) |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 200.0 |  |
Petra Pharma Corporation (Petra) |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  |  | $ 174.8 |
Disarm Therapeutics, Inc. |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |
Acquired IPR&D Expense |  |  |  |  | $ 126.3 |  |

X
- Definition Payments for Asset Acquisitions + References No definition available. + Details
Name: | lly_PaymentsForAssetAcquisitions
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_BioMarinPharmaceuticalIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_FoghornTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_RigelPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PrecisionBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_InnoventBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_PetraPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=lly_DisarmTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |